Natural killer cell engineering for cellular therapy of cancer

Area of Science:

• Immunology
• Cell Biology
• Oncology

Background:

• Natural killer (NK) cells are crucial for identifying and eliminating transformed cells.
• NK cell function is regulated by a complex interplay of activating and inhibitory surface receptors.
• Effective NK cell-based cancer immunotherapy necessitates robust methods for generating sufficient effector cells.

Purpose of the Study:

• To describe a method for expanding and genetically modifying NK cells for cancer immunotherapy.
• To detail the engineering of K562 leukemia cells to support NK cell expansion.
• To outline the adaptation of these methods for clinical-grade, large-scale production.

Main Methods:

• Genetically engineered K562 leukemia cells expressing membrane-bound interleukin-15 and 4-1BB ligand were used for NK cell expansion.
• Expanded NK cells were subsequently transduced with chimeric antigen receptors (CARs) to enhance tumor-specific cytotoxicity.
• The entire process was optimized for Current Good Manufacturing Practice (cGMP) conditions.

Main Results:

• The described method enables the generation of a sufficient number of activated NK cells.
• Genetically modified NK cells exhibit enhanced tumor-specific cytotoxic activity.
• The methods have been successfully scaled for clinical application, supporting active trials.

Conclusions:

• The developed NK cell expansion and genetic modification techniques provide a viable strategy for cancer immunotherapy.
• These cGMP-compliant methods support the advancement of NK cell-based clinical trials.
• Further development holds promise for improving NK cell therapy efficacy in cancer treatment.